HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the second quarter and half year ended September 30, 2016 under International Financial Reporting Standards (IFRS).
Q2 FY17: Key Highlights
• Revenues at Rs. 35.9 billion: QoQ growth: 11%
Q2 FY17: Key Highlights
• Revenues at Rs. 35.9 billion: QoQ growth: 11%
